Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:21 UTC |
Lawver Teri LSVP & Chief Commercial Officer
|
GrantIncentive Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001960596-26-000004 · form4-06292026_080655.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:21 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
GrantIncentive Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001838114-26-000002 · form4-06292026_080612.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:20 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
GrantIncentive Stock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001648010-26-000002 · form4-06292026_080627.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:19 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
GrantIncentive Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001718112-26-000002 · form4-06292026_080629.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:18 UTC |
Martin Samuel BatesSVP AND CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001709024-26-000004 · form4-06292026_080644.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:17 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
GrantIncentive Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001709113-26-000002 · form4-06292026_080653.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:17 UTC |
Crowley ElizabethSR. VP & CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001681854-26-000002 · form4-06292026_080604.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:16 UTC |
PEPIN RONALDSR. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001214504-26-000002 · form4-06292026_080606.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:15 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 115,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001429931-26-000002 · form4-06292026_080620.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:14 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001429933-26-000002 · form4-06292026_080621.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:12 UTC |
Torres DeniceDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001820278-26-000008 · form4-06292026_080636.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:11 UTC |
Jain RitaDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001707797-26-000012 · form4-06292026_080641.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:10 UTC |
NEIL GARRY ARTHURDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001586785-26-000008 · form4-06292026_080652.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:10 UTC |
Cohen CherylDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001529371-26-000005 · form4-06292026_080658.xml · derivative · entry 1 Cohen Cheryl · CIK 0001529371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:09 UTC |
Brownlie Keith LDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001518575-26-000002 · form4-06292026_080611.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:08 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001198578-26-000002 · form4-06292026_080625.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:07 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001218815-26-000002 · form4-06292026_080622.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:06 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001131148-26-000002 · form4-06292026_080629.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:23 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionIncentive Stock Option (Right to Buy) · Derivative | 4,817 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001709024-26-000002 · form4-01062026_090142.xml · derivative · entry 2 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,815 Underlying: Common Stock · 4,817 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of June 18, 2024, the option is fully vested. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:23 UTC |
Martin Samuel BatesSVP AND CFO
|
Exercise / conversionCommon Stock | 4,817 | $10.38 | $50,000.46 |
DisclosureSEC source: 0001709024-26-000002 · form4-01062026_090142.xml · nonDerivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:06 UTC |
PEPIN RONALDSR. VP & CBO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001214504-25-000007 · form4-12172025_091230.xml · derivative · entry 4 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2029-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: As of June 19, 2023, the option is fully vested. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:06 UTC |
PEPIN RONALDSR. VP & CBO
|
Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001214504-25-000007 · form4-12172025_091230.xml · derivative · entry 3 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 8,333 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F3 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. F1 · derivative.underlying_shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:06 UTC |
PEPIN RONALDSR. VP & CBO
|
Exercise / conversionCommon Stock | 11,000 | $2.78 | $30,580.00 |
DisclosureSEC source: 0001214504-25-000007 · form4-12172025_091230.xml · nonDerivative · entry 2 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:06 UTC |
PEPIN RONALDSR. VP & CBO
|
Exercise / conversionCommon Stock | 8,333 | $9.02 | $75,134.49 |
DisclosureSEC source: 0001214504-25-000007 · form4-12172025_091230.xml · nonDerivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F1 · price: On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:20 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
SaleCommon Stock | 4,166 | $29.10 | $121,209.77 |
DisclosureSEC source: 0001838114-25-000007 · form4-12082025_091231.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,796 Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 15,750 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 7 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 15,750 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 26,672 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 6 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,672 shares Expires 2030-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: As of June 18, 2024, the option is fully vested. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 6,876 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · derivative · entry 5 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,876 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: As of June 13, 2022, the option is fully vested. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
SaleCommon Stock | 49,298 | $24.00 | $1,183,176.65 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 4 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,833 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionCommon Stock | 15,750 | $22.48 | $354,060.00 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 3 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionCommon Stock | 26,672 | $10.38 | $276,855.36 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 2 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:17 UTC |
Wright Richard M.Former Officer
|
Exercise / conversionCommon Stock | 6,876 | $9.02 | $61,997.45 |
DisclosureSEC source: 0001646423-25-000007 · form4-11172025_091104.xml · nonDerivative · entry 1 Wright Richard M. · CIK 0001646423 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:12 UTC |
Lawver Teri LSVP & Chief Commercial Officer
|
GrantISO (right to buy) · Derivative | 100,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001960596-25-000008 · form4-11122025_091122.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-11-10 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
SaleCommon Stock | 430 | $25.42 | $10,928.45 |
DisclosureSEC source: 0001415889-25-022069 · form4-08152025_080825.xml · nonDerivative · entry 2 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,962 Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:07 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
SaleCommon Stock | 341 | $23.95 | $8,167.46 |
DisclosureSEC source: 0001415889-25-022069 · form4-08152025_080825.xml · nonDerivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,392 F1 · balance_after: Includes 269 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:22 UTC |
Cavanaugh SarahSVP OF CORP AFFAIRS & ADMIN.
|
GrantIncentive Stock Option (right to buy) · Derivative | 78,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016260 · form4-06092025_080647.xml · derivative · entry 1 Cavanaugh Sarah · CIK 0001709113 · SVP OF CORP AFFAIRS & ADMIN. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:22 UTC |
Crowley ElizabethSR. VP & CPDO
|
GrantIncentive Stock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016257 · form4-06092025_080605.xml · derivative · entry 1 Crowley Elizabeth · CIK 0001681854 · SR. VP & CPDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:21 UTC |
Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
|
GrantIncentive Stock Option (right to buy) · Derivative | 82,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016255 · form4-06092025_080648.xml · derivative · entry 1 Heath-Chiozzi Margo · CIK 0001718112 · SVP OF REGULATORY AFFAIRS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,000 Underlying: Common Stock · 82,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:18 UTC |
Jimenez Freddy A.SVP & GENERAL COUNSEL
|
GrantIncentive Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016244 · form4-06092025_080659.xml · derivative · entry 1 Jimenez Freddy A. · CIK 0001838114 · SVP & GENERAL COUNSEL 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:17 UTC |
Martin Samuel BatesSVP AND CFO
|
GrantIncentive Stock Option (right to buy) · Derivative | 81,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016242 · form4-06092025_080614.xml · derivative · entry 1 Martin Samuel Bates · CIK 0001709024 · SVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:15 UTC |
Young Diane C.SVP, CHIEF MEDICAL OFFICER
|
GrantIncentive Stock Option (right to buy) · Derivative | 72,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016238 · form4-06092025_080613.xml · derivative · entry 1 Young Diane C. · CIK 0001648010 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:16 UTC |
PEPIN RONALDSR. VP & CBO
|
GrantIncentive Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016241 · form4-06092025_080610.xml · derivative · entry 1 PEPIN RONALD · CIK 0001214504 · SR. VP & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:13 UTC |
Marucci Anthony SDirector · PRESIDENT & CEO
|
GrantIncentive Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016227 · form4-06092025_080629.xml · derivative · entry 1 Marucci Anthony S · CIK 0001429933 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:14 UTC |
KELER TIBOREXECUTIVE VP & CSO
|
GrantIncentive Stock Option (right to buy) · Derivative | 93,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016230 · form4-06092025_080623.xml · derivative · entry 1 KELER TIBOR · CIK 0001429931 · EXECUTIVE VP & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:12 UTC |
Torres DeniceDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016226 · form4-06092025_080642.xml · derivative · entry 1 Torres Denice · CIK 0001820278 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 5, 2026. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:10 UTC |
Jain RitaDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016225 · form4-06092025_080641.xml · derivative · entry 1 Jain Rita · CIK 0001707797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:10 UTC |
NEIL GARRY ARTHURDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016222 · form4-06092025_080657.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:09 UTC |
PENNER HARRY JRDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016220 · form4-06092025_080604.xml · derivative · entry 1 PENNER HARRY JR · CIK 0001131148 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC |
CONRAD HERBERT JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016219 · form4-06092025_080631.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC |
MARINO JAMES JDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016217 · form4-06092025_080645.xml · derivative · entry 1 MARINO JAMES J · CIK 0001198578 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.